


PHARMACEUTICAL 2022



PLIANT THERAPEUTICS INC. Rank 267 of 475





PHARMACEUTICAL 2022



PLIANT THERAPEUTICS INC. Rank 267 of 475

The relative strengths and weaknesses of PLIANT THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PLIANT THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 124% points. The greatest weakness of PLIANT THERAPEUTICS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is -145%, being 132% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	209,441
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,831
Liabilities, Non-Current	5,325
Other Assets	7,168
Other Compr. Net Income	-169
Other Expenses	0
Other Liabilities	0
Other Net Income	272
Property and Equipment	4,606
Research and Development	77,549
Revenues	7,572
Selling, General and Administrative Expense	27,558

Output Variable	Value in 1000 USD
Assets	221,215
Liabilities	22,156
Expenses	105,107
Stockholders Equity	199,059
Net Income	-97,263
Comprehensive Net Income	-97,348
Economic Capital Ratio	-145%